Mycoplasma mycoides subsp. capri and Contagious Caprine Pleuropneumonia (CCPP): Etiology, Pathogenesis, and Diagnostic Management

Etiology and Taxonomic Classification

Mycoplasma mycoides subsp. capri (Mmc) is a cell wall deficient bacterium belonging to the class Mollicutes, order Mycoplasmatales, and family Mycoplasmataceae. It is a member of the Mycoplasma mycoides cluster, a group of closely related pathogenic mycoplasmas that cause significant respiratory, mammary, and articular disease in ruminants. The taxonomic history of Mmc is complex. Historically, strains formerly classified as Mycoplasma mycoides subsp. mycoides large colony type (LC) have been reclassified as serovars of Mmc based on genetic and serological evidence [1, 2]. This reclassification was supported by multilocus sequence typing (MLST) and protein profiling studies that demonstrated insufficient divergence to warrant separate subspecies status [3, 4]. The current taxonomic framework recognizes Mmc as a distinct subspecies, with the type strain being PG3 [1].

Mmc is distinguished from other members of the M. mycoides cluster, such as Mycoplasma capricolum subsp. capripneumoniae (Mccp), the primary etiological agent of classical contagious caprine pleuropneumonia (CCPP), and Mycoplasma mycoides subsp. mycoides small colony type (SC), the agent of contagious bovine pleuropneumonia (CBPP). While Mccp is the classic cause of CCPP, Mmc is frequently isolated from cases of caprine pleuropneumonia and is considered a significant contributor to the disease complex, particularly in regions where both pathogens circulate [5, 6]. The clinical and pathological overlap between infections caused by Mmc and Mccp necessitates molecular differentiation for accurate diagnosis and epidemiological surveillance [5].

Epidemiology and Host Range

Mmc is a pathogen primarily of goats (Capra hircus), although it has been isolated from sheep and, under experimental conditions, can cause disease in calves co-infected with immunosuppressive agents such as Trypanosoma congolense [49]. The geographic distribution of Mmc is global, with confirmed reports from Europe, Asia, Africa, the Americas, and Australia [7, 8, 9, 42]. The organism is endemic in many regions with intensive goat production, particularly in the Mediterranean basin, the Middle East, South Asia, and parts of Africa [3, 10, 6].

Transmission occurs primarily via direct contact through aerosolized respiratory secretions. Close confinement during transport, housing, or at markets facilitates rapid spread within and between herds. Subclinically infected carriers, including animals that have recovered from acute disease, play a critical role in maintaining the pathogen within a population. The organism can persist in the upper respiratory tract and in the male reproductive tract, with evidence of shedding in semen and milk [11, 12, 13]. The survival of Mmc in the environment is limited due to its lack of a cell wall, but it can remain viable in milk and other organic material for several days under cool, moist conditions [13]. Fecal excretion has also been documented, suggesting a potential environmental contamination route [14].

Pathogenesis and Virulence Factors

The pathogenesis of Mmc infection is multifactorial, involving a combination of immune evasion, surface antigen variation, and the induction of a dysregulated inflammatory response. As a cell wall deficient organism, Mmc relies on its plasma membrane, which is enriched with lipoproteins and a capsular polysaccharide (CPS), for interaction with the host.

Capsular Polysaccharide and Phenotypic Diversity

A key virulence mechanism is the phase-variable expression of CPS. Recent work has demonstrated that Mmc can switch CPS expression on and off, generating phenotypic diversity within a clonal population [15]. This switching has profound effects on host-pathogen interactions. The highly virulent strain GM12, which expresses CPS, exhibits an immunological furtiveness phenotype. It induces minimal host cell death and only moderate activation of antigen-presenting cells, allowing it to survive and replicate within monocyte-derived macrophages (MDMs) [15]. This intracellular survival within macrophages is a critical strategy for dissemination and persistence, as the organism can be transported to distant anatomical sites, including the lungs, joints, and mammary gland.

In contrast, a CPS-deficient mutant, which exposes surface lipoproteins, triggers a robust and damaging inflammatory response. This mutant induces significant cell death, suppresses major histocompatibility complex (MHC) expression on antigen-presenting cells, and stimulates the secretion of pro-inflammatory cytokines and chemokines [15]. This inflammatory cascade is a clinical hallmark of acute disease, leading to the severe fibrinous pleuropneumonia observed in affected animals. The ability to switch between these two phenotypes (covert survival versus overt inflammation) allows Mmc to establish infection, disseminate, and then trigger the acute clinical syndrome.

Lipoproteins and Immunogenicity

Surface lipoproteins are major immunogens and play a central role in pathogenesis. The lipoprotein LppA is a conserved 62-kDa protein found in both Mmc and the former M. mycoides subsp. mycoides LC strains [16]. It is a target for serological detection and has been used in PCR-based identification assays [16, 48]. A proteomic analysis of Mmc membrane proteins identified 13 immunogenic proteins, including metabolic enzymes such as pyruvate dehydrogenase, dihydrolipoamide acetyltransferase, and phosphopyruvate hydratase, as well as translation elongation factors [17]. These proteins are potential biomarkers for serological diagnosis. In silico analysis of the predicted lipoproteome has further identified conserved, non-cross-reactive lipoproteins suitable for immunodiagnostic development [44].

Restriction-Modification Systems and Phase Variation

The Mmc genome encodes a Type III restriction-modification (R-M) system (MmyCI) that recognizes the sequence 5'-TGAG-3' [35]. The expression of the methyltransferase subunit is phase-variable due to a tract of 12 consecutive AG dinucleotide repeats within the coding region. Slipped-strand mispairing during replication can alter the number of repeats, leading to a frameshift and premature termination. This on/off switching of the R-M system can modulate gene expression across the genome and may contribute to phenotypic diversity and immune evasion [35].

Clinical Signs

The clinical presentation of Mmc infection in goats is highly variable, ranging from peracute to chronic forms. The disease is often referred to as contagious caprine pleuropneumonia (CCPP) when it presents with severe respiratory signs, although classical CCPP is specifically attributed to Mccp. Mmc is also a causative agent of contagious agalactia in goats, a syndrome characterized by mastitis, arthritis, and keratoconjunctivitis [17, 18].

Respiratory Form (CCPP-like)

The respiratory form is the most economically significant. The incubation period is typically 2 to 6 days following exposure.

• Peracute: Sudden death without premonitory signs. This is more common in kids and young adults.
• Acute: Marked pyrexia (40.5 to 42.0 degrees Celsius), severe dyspnea with open-mouth breathing, a painful, dry cough, and serous to mucopurulent nasal discharge. Affected animals stand with their heads extended, elbows abducted, and may show signs of pleuritic pain. Anorexia and rapid weight loss are common. Mortality can be high, approaching 50 to 80 percent in naive herds [8, 19].
• Subacute/Chronic: Milder respiratory signs, intermittent cough, poor growth, and reduced milk yield. Chronically infected animals may become carriers, serving as a source of infection for naive cohorts.

Extrapulmonary Manifestations

• Mastitis (Contagious Agalactia): Acute or chronic inflammation of the mammary gland, leading to agalactia. The milk may appear thick, purulent, or clotted.
• Arthritis: Swelling and lameness in one or more joints, particularly the carpal and tarsal joints. This is more common in kids.
• Keratoconjunctivitis: Ocular discharge, conjunctival hyperemia, and corneal opacity.
• Septicemia: In young kids, Mmc can cause a septicemic disease with polyarthritis and polyserositis, often without prominent respiratory signs [20].

Pathology

Gross Lesions

The hallmark lesions of Mmc-induced pleuropneumonia are unilateral or bilateral fibrinous pleuropneumonia. The thoracic cavity often contains a large volume of straw-colored to serosanguinous pleural fluid with fibrin clots. The lungs are consolidated, hepatized, and may show a marbled appearance due to the interlobular septa being distended with fibrin and edema [21, 47]. Fibrinous adhesions between the visceral and parietal pleura are common. In the peracute form, the lungs may be edematous and congested without frank consolidation.

In cases of mastitis, the affected mammary gland is firm, swollen, and may contain purulent or caseous exudate. Arthritic joints show thickening of the synovial membrane and an increase in turbid synovial fluid.

Histopathology

Histological examination reveals a severe, acute fibrinous bronchopneumonia with necrotizing bronchiolitis. Alveoli are filled with fibrin, neutrophils, and macrophages. The interlobular septa are markedly distended by edema, fibrin, and inflammatory cells, leading to the characteristic gross marbling. Lymphatic vessels are dilated and thrombosed. Immunohistochemistry can demonstrate abundant mycoplasmal antigen within the cytoplasm of macrophages and neutrophils, as well as extracellularly within the exudate [21, 20].

Diagnostics

Accurate diagnosis of Mmc infection requires a combination of clinical, pathological, and laboratory methods. Due to the clinical overlap with Mccp and other respiratory pathogens, molecular confirmation is essential.

Sample Collection

Appropriate samples include nasal swabs, transtracheal washes, pleural fluid, lung tissue (from the interface between consolidated and normal tissue), and synovial fluid. For carrier detection, ear swabs have been shown to be a useful, non-invasive sample [22]. Milk and semen samples are also valuable for detecting mammary and reproductive tract infections [11, 13].

Culture and Isolation

Mmc is a fastidious organism requiring specialized media (e.g., Hayflick's or Friis medium) supplemented with serum and sterols. Colonies on solid media exhibit the characteristic "fried egg" appearance due to the dense central zone of growth penetrating the agar and the peripheral zone of surface growth. Isolation is time-consuming (3 to 10 days) and has low sensitivity, particularly from samples with low bacterial loads or from animals that have received antimicrobial therapy [22]. A rapid photometric assay for growth has been described but is not widely used in routine diagnostics [45].

Molecular Diagnostics

Polymerase chain reaction (PCR) is the method of choice for rapid and sensitive detection of Mmc.

• Conventional PCR and PCR-RFLP: PCR assays targeting the lppA gene or the 16S rRNA gene can identify members of the M. mycoides cluster [16, 23]. Restriction fragment length polymorphism (RFLP) analysis of PCR products can differentiate Mmc from Mccp and other closely related species [23].
• Real-Time PCR (qPCR): TaqMan-based real-time PCR assays targeting specific Mmc genes (e.g., MLC_0560) offer high sensitivity and specificity, with detection limits as low as 58 copies per microliter [24]. These assays are quantitative and can be used to monitor bacterial load.
• High-Resolution Melting (HRM) Curve Analysis: HRM analysis is a powerful post-PCR technique that distinguishes amplicons based on their melting temperature (Tm). A duplex HRM assay targeting the MLC_0560 gene of Mmc and the MCCPF38_00984 gene of Mccp can simultaneously detect and differentiate these two pathogens in a single reaction [5]. This method has demonstrated a high coincidence rate (94.8%) with qPCR and superior sensitivity compared to culture [5].

Serological Diagnostics

Serological tests are useful for herd-level screening and epidemiological studies.

• Complement Fixation Test (CFT): The CFT has been used for decades and shows good sensitivity (93.33%) and moderate specificity (72.27%) for detecting antibodies against Mmc in goats [9]. It is a valuable tool for identifying animals that have had prior exposure.
• Enzyme-Linked Immunosorbent Assay (ELISA): Commercial and in-house ELISA kits using whole-cell antigens or recombinant lipoproteins (e.g., LppA) are available. These assays are more suitable for large-scale testing than CFT. The identification of specific immunogenic proteins has improved the specificity of serological diagnosis [17, 44].

Diagnostic Workflow

The following Mermaid diagram illustrates a recommended diagnostic decision tree for suspected CCPP cases.

graph TD
    A[Goat with respiratory signs: fever, cough, dyspnea], > B{Clinical examination & history}
    B, > C[Collect samples: nasal swab, pleural fluid, lung tissue]
    C, > D{Initial laboratory testing}
    D, > E[DNA extraction & Real-time PCR / HRM analysis]
    E, > F{Result: Mmc positive?}
    F, Yes, > G[Confirm diagnosis: Mycoplasma mycoides subsp. capri infection]
    F, No, > H{Result: Mccp positive?}
    H, Yes, > I[Confirm diagnosis: Mycoplasma capricolum subsp. capripneumoniae infection]
    H, No, > J[Consider other pathogens: e.g., Pasteurella, Mannheimia, viruses]
    G, > K[Antimicrobial sensitivity testing (optional)]
    K, > L[Implement treatment & control measures]
    I, > L
    J, > M[Further diagnostic workup]
    D, > N[Optional: Culture on selective media]
    N, > O[Incubate 3-10 days]
    O, > P[Identify colonies: PCR or immunoblotting]
    P, > G
    D, > Q[Optional: Serology (CFT or ELISA) for herd screening]
    Q, > R[Interpret titers: positive indicates prior exposure]

Treatment

Antimicrobial therapy is the primary intervention for clinical cases. However, treatment is most effective when initiated early in the course of disease. Due to the lack of a cell wall, Mmc is intrinsically resistant to beta-lactam antibiotics (e.g., penicillins, cephalosporins) and to sulfonamides.

Antimicrobial Susceptibility

In vitro susceptibility testing has identified several classes of antimicrobials with activity against Mmc.

• Macrolides: Tylosin and erythromycin have shown excellent in vitro activity and are considered drugs of choice in many regions [36].
• Tetracyclines: Oxytetracycline, doxycycline, and chlortetracycline are effective and widely used [36].
• Fluoroquinolones: Enrofloxacin and danofloxacin are effective, but resistance mechanisms, including mutations in the quinolone resistance-determining regions (QRDRs) of DNA gyrase (gyrA) and topoisomerase IV (parC), have been documented [25].
• Pleuromutilins: Tiamulin is highly active against mycoplasmas and is a valuable option.
• Aminoglycosides: Gentamicin and spectinomycin have variable activity.

Antimicrobial Resistance

The emergence of antimicrobial resistance in Mmc is a growing concern. Resistance to macrolides and tetracyclines has been reported, and the potential for horizontal gene transfer among Mollicutes may facilitate the spread of resistance determinants [36]. In vitro studies have also explored the efficacy of plant-derived antimicrobial extracts, with oregano oil and goldenseal root extract showing inhibitory activity, though these are not standard veterinary treatments [26].

Clinical Management

Treatment should be based on antimicrobial sensitivity testing whenever possible. In the absence of sensitivity data, a macrolide (e.g., tylosin at 10-20 mg/kg body weight) or a tetracycline (e.g., oxytetracycline at 10-20 mg/kg) is a reasonable first choice. Treatment courses of 5 to 7 days are typical. Supportive care, including non-steroidal anti-inflammatory drugs (NSAIDs) for pyrexia and pleuritic pain, and fluid therapy for dehydrated animals, is critical.

Control and Prevention

Control of Mmc infection relies on a combination of biosecurity, management practices, and vaccination.

Biosecurity

• Quarantine: New animals should be quarantined for at least 30 days and tested (e.g., by PCR on nasal swabs) before introduction to the herd.
• Herd Closure: Maintaining a closed herd is the most effective way to prevent introduction.
• Segregation: Separate age groups and avoid mixing animals from different sources.
• Sanitation: Disinfect housing and equipment. Mycoplasmas are susceptible to common disinfectants, including quaternary ammonium compounds and bleach.

Eradication

In infected herds, a test-and-cull strategy can be employed. Serological testing (CFT or ELISA) combined with PCR testing of high-risk animals (e.g., those with chronic cough or mastitis) can identify carriers. Removal of positive animals, combined with strict biosecurity, can eliminate the infection from a herd.

Vaccination

Vaccination is a key component of control in endemic areas. Both inactivated (killed) and live-attenuated vaccines have been developed. Inactivated vaccines provide partial protection and can reduce clinical severity and mortality but may not prevent infection or carriage. Live-attenuated vaccines can induce stronger and longer-lasting immunity but carry a risk of reversion to virulence. No universally standardized commercial vaccine exists for Mmc, and autogenous vaccines are sometimes used in specific regions.

Integrated Control

An integrated approach combining biosecurity, strategic antimicrobial use, and vaccination is the most sustainable strategy for controlling Mmc and reducing the economic impact of CCPP in goat herds.

References

[1] Manso-Silván, L., Vilei, E., Sachse, K., et al. (2009). Mycoplasma leachii sp. nov. as a new species designation for Mycoplasma sp. bovine group 7 of Leach, and reclassification of Mycoplasma mycoides subsp. mycoides LC as a serovar of Mycoplasma mycoides subsp. capri. International Journal of Systematic and Evolutionary Microbiology.

[2] Vilei, E., Korczak, B., Frey, J. (2006). Mycoplasma mycoides subsp. capri and Mycoplasma mycoides subsp. mycoides LC can be grouped into a single subspecies. Veterinary Research.

[3] Tatay-Dualde, J., Prats-van der Ham, M., de la Fe, C., et al. (2016). Multilocus sequence typing of Mycoplasma mycoides subsp. capri to assess its genetic variability in a contagious agalactia endemic area. Veterinary Microbiology.

[4] Leach, R., Costas, M., Mitchelmore, D. L. (1989). Relationship between Mycoplasma mycoides subsp. mycoides ('large-colony' strains) and M. mycoides subsp. capri, as indicated by numerical analysis of one-dimensional SDS-PAGE protein patterns. Journal of General Microbiology.

[5] Zhang, J., Liu, Z., Jiang, J., et al. (2021). Rapid detection of Mycoplasma mycoides subsp. capri and Mycoplasma capricolum subsp. capripneumoniae using high-resolution melting curve analysis. Scientific Reports.

[6] Rahman, H., Saddique, U., Hassan, Z., et al. (2018). The Predominant Incidence of Mycoplasma mycoides subsp. capri in Suspected Cases of Contagious Caprine Pleuropneumonia in Sheep and Goats of Northern Pakistan.

[7] CABI Compendium. (2022). Mycoplasma mycoides subsp. capri.

[8] Hernández, L., López, J., St-Jacques, M., et al. (2006). Mycoplasma mycoides subsp. capri associated with goat respiratory disease and high flock mortality. The Canadian Veterinary Journal.

[9] Corona-Vargas, J. L., Vicencio-Mallén, M. A., Salmerón-Sosa, F., et al. (2016). Detection of Antibodies against Mycoplasma mycoides subsp. capri in Goats with the Complement Fixation Test.

[10] Subbaiyan, A., Thomas, P., Sankar, M., et al. (2020). Multilocus sequence typing of pathogenic Mycoplasma mycoides subsp. capri reveals the predominance of a novel clonal complex among isolates from goats in India. Archives of Microbiology.

[11] Gómez-Martín, Á., Uc, N., Vieira, L., et al. (2015). Survival capacity of Mycoplasma agalactiae and Mycoplasma mycoides subsp capri in the diluted semen of goat bucks and their effects on sperm quality. Theriogenology.

[12] Gómez-Martín, Á., de la Fe, C., Amores, J., et al. (2012). Anatomic location of Mycoplasma mycoides subsp. capri and Mycoplasma agalactiae in naturally infected goat male auricular carriers. Veterinary Microbiology.

[13] Amores, J., Sánchez, A., Gómez Martín, Á., et al. (2010). Viability of Mycoplasma agalactiae and Mycoplasma mycoides subsp. capri in goat milk samples stored under different conditions. Veterinary Microbiology.

[14] Szeredi, L., Tenk, M., Dán, Á. (2003). Infection of two goatherds with Mycoplasma mycoides subsp. capri in Hungary, evidence of a possible faecal excretion. Journal of Veterinary Medicine B.

[15] Yimthin, T., Bourgeon, M., Zhang, J., et al. (2025). Capsular polysaccharide of Mycoplasma mycoides subsp. capri contributes to phenotypic diversity promoting distinctive immune responses. PLoS Pathogens.

[16] Monnerat, M. P., Thiaucourt, F., Poveda, J., et al. (1999). Genetic and Serological Analysis of Lipoprotein LppA in Mycoplasma mycoides subsp. mycoides LC and Mycoplasma mycoides subsp. capri. Clinical Diagnostic Laboratory Immunology.

[17] Corona, L., Cillara, G., Tola, S. (2013). Proteomic approach for identification of immunogenic proteins of Mycoplasma mycoides subsp. capri. Veterinary Microbiology.

[18] Amores, J., Sánchez, A., Gómez-Martín, Á., et al. (2012). Surveillance of Mycoplasma agalactiae and Mycoplasma mycoides subsp. capri in dairy goat herds.

[19] Shah, S. S. A., Sadique, U., Hassan, Z., et al. (2017). Clinico-pathological profile and frequency of Mycoplasma mycoides subsp. capri infection in goats in northern zone of Khyber-Pakhtunkhwa, Pakistan.

[20] Rodríguez, J. L., Gutiérrez, C., Brooks, D., et al. (1998). A pathological and immunohistochemical study of goat kids undergoing septicaemic disease caused by Mycoplasma capricolum subsp. capricolum, Mycoplasma mycoides subsp. capri and Mycoplasma mycoides subsp. mycoides (large colony type). *Zentralblatt fur

[21] Sahoo, M., Thakor, J., Kumar, P., et al. (2025). Pathomorphological findings and antigen distribution in goats experimentally infected with Mycoplasma mycoides subsp. capri (Mmc). Proceedings of Indian National Science Academy.

[22] Amores, J., Corrales, J., Gómez Martín, Á., et al. (2010). Comparison of culture and PCR to detect Mycoplasma agalactiae and Mycoplasma mycoides subsp. capri in ear swabs taken from goats. Veterinary Microbiology.

[23] Cillara, G., Manca, M. G., Longheu, C., et al. (2015). Discrimination between Mycoplasma mycoides subsp. capri and Mycoplasma capricolum subsp. capricolum using PCR-RFLP and PCR. The Veterinary Journal.

[24] Lin, Y., Jiang, J., Zhang, J., et al. (2019). Development of a TaqMan real-time PCR for detection of the Mycoplasma mycoides subsp. capri. Small Ruminant Research.

[25] Antunes, N. T., Assunção, P., Poveda, J., et al. (2015). Mechanisms involved in quinolone resistance in Mycoplasma mycoides subsp. capri. The Veterinary Journal.

[26] Arjoon, A. V., Saylor, C., May, M. (2012). In Vitro efficacy of antimicrobial extracts against the atypical ruminant pathogen Mycoplasma mycoides subsp. capri. BMC Complementary and Alternative Medicine.

[27] Paterna, A., Tatay-Dualde, J., Amores, J., et al. (2016). In vitro assessment of the antimicrobial susceptibility of caprine isolates of Mycoplasma mycoides subsp. capri. The Veterinary Journal.

[28] Wang, X., Wang, Y., Huang, H., et al. (2018). Understanding the metabolism of Mycoplasma mycoides subsp. capri in vitro by a transcriptomic analysis.

[29] Al-Aubaidi, J. M., Dardiri, A. H., Fabricant, J. (1972). Biochemical Characterization and Antigenic Relationship of Mycoplasma mycoides subsp. mycoides, Freundt and Mycoplasma mycoides subsp. capri (Edward) Freundt.

[30] Archer, D. (1975). Modification of the membrane composition of Mycoplasma mycoides subsp. capri by the growth medium. Journal of General Microbiology.

[31] Allam, A. B., Reyes, L., Assad-Garcia, N., et al. (2010). Enhancement of Targeted Homologous Recombination in Mycoplasma mycoides subsp. capri by Inclusion of Heterologous recA. Applied and Environmental Microbiology.

[32] Manimaran, K., Singh, V. (2017). Rapid detection of infection due to Mycoplasma mycoides subsp. capri in experimental goats by PCR assay.

[33] Xu, C., Hao, Y., Zhang, L., et al. (2014). Molecular cloning and immune response analysis of putative variable lipoproteins from Mycoplasma mycoides subsp capri. Genetics and Molecular Research.

[34] Archer, D., Gale, E. F. (1975). Antagonism by sterols of the action of amphotericin and filipin on the release of potassium ions from Candida albicans and Mycoplasma mycoides subsp. capri. Journal of General Microbiology.